Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities: 2014-2024

Historic Other Non-Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Dec 2024 value amounting to $20.9 million.

  • Amphastar Pharmaceuticals' Other Non-Current Liabilities rose 8.26% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of $20.9 million for FY2024, which is 7.80% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Other Non-Current Liabilities stood at $20.9 million, which was down 7.80% from $22.7 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $22.7 million during FY2023, with a 5-year trough of $13.2 million in FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Other Non-Current Liabilities had a median value of $20.9 million in 2024 and averaged $19.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 55.98% in 2023, then fell by 7.80% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $13.2 million in 2020, then climbed by 18.48% to $15.7 million in 2021, then decreased by 6.95% to $14.6 million in 2022, then surged by 55.98% to $22.7 million in 2023, then decreased by 7.80% to $20.9 million in 2024.